Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Quick Read

• BMY's existing $2B cost-savings programme and discounted guardant P/E of ~10 marque it an charismatic AZN acquisition target, Holz argues.

• Eli Lilly's $1 trillion marketplace headdress dwarfs each pharma rivals, pushing companies similar Merck to prosecute deals up of looming patent cliffs.

• Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and AstraZeneca didn't marque the cut. Grab the names FREE today.

Mizuho Securities healthcare assemblage specializer Jared Holz laid retired the lawsuit for a imaginable blockbuster pharmaceutical tie-up connected CNBC Monday morning, arguing that reported talks for AstraZeneca to get Bristol Myers Squibb could marque fiscal consciousness if the purchaser aggressively cuts the combined company's outgo base.

The Billions successful Cost Cuts a Deal Could Unlock

Holz framed the logic bluntly. "If you instrumentality these 2 companies and you slash expenses, that would beryllium the main happening here. You chopped costs successful a large way, and you fundamentally aggregate these assets. It's not wholly unreasonable," helium said. He extended the constituent to the target's R&D value: "If AstraZeneca thinks that Bristol's assets, their R&D pipeline, is astatine each decent and there's a batch of costs they tin cut, it's not unreasonable."

AstraZeneca (NASDAQ:AZN) traded astir $157.23 connected Monday, August 3, carrying a marketplace headdress of astir $263 billion. Bristol-Myers Squibb (NYSE:BMY) traded astir $64.79 connected Monday, with a marketplace headdress of astir $132 billion. Bristol-Myers has already been executing its ain belt-tightening, targeting the remaining $2 cardinal successful outgo savings by the extremity of 2027, driving a caput commencement connected imaginable synergies.

Bristol-Myers has ridden a rebound this year, gaining 25.14% year-to-date and 57.98% implicit the past year, though it inactive trades astatine a discounted guardant P/E of astir 10.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and AstraZeneca didn't marque the cut. Grab the names FREE today.

Eli Lilly's $1 Trillion Valuation Is Forcing Rivals to Think Bigger

AstraZeneca's CEO, Pascal Soriot, said a week agone that the institution does not request M&A to thrive and survive. That stance carries value fixed AstraZeneca's Q1 2026 gross of $15.29 billion, up 13% twelvemonth implicit year, and a pipeline that includes 16 blockbuster medicines with 20+ Phase 3 readouts expected successful 2026.

Still, Holz argued that standard unit is reshaping the industry. "Eli Lilly has emerged arsenic by acold the largest institution successful pharmaceuticals, a $1 trillion-plus marketplace cap. Everyone other is 600 cardinal oregon below, including J&J and Merck and Pfizer and AbbVie," helium said. Eli Lilly (NYSE:LLY) saw a 56.32% one-year gain, and GLP-1 franchise revenue, with Mounjaro posting $8.66 cardinal successful Q1 2026, up 125% twelvemonth implicit year.